SCHEMBL25844123

SCHEMBL25844123

COc1cc(-c2cn(C)c(=O)c(C)c2C)cc(Cl)c1CN1CCC(C(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 13/20 0.52
BRD4 O60885 9/20 0.52
BRD7 Q9NPI1 9/20 0.52
BRD2 P25440 5/20 0.52
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 1/20 0.40
KCNH2 Q12809 1/20 0.40
HTR2C P28335 2/20 0.39
HTR2A P28223 1/20 0.37
EZH2 Q15910 1/20 0.35
TAF1 P21675 1/20 0.34
TGFBR1 P36897 1/20 0.34
BRPF1 P55201 1/20 0.34
ACVR1 Q04771 1/20 0.34
BPTF Q12830 1/20 0.34
TAF1L Q8IZX4 1/20 0.34
CREBBP Q92793 1/20 0.34
CECR2 Q9BXF3 1/20 0.34
BAZ2B Q9UIF8 1/20 0.34
ATAD2B Q9ULI0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23798071 0.90 BRD9 (0.53) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL23797634 0.87 BRD4 (0.53) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL25091102 0.85 CYP3A4 (0.47) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL23798072 0.83 BRD9 (0.50) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL25091531 0.83 BRD4 (0.42) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL23797618 0.83 BRD9 (0.57) BRD9BRD7CYP3A4CYP2C19KCNH2
SCHEMBL23798990 0.81 BRD9 (0.44) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL25091100 0.80 BRD4 (0.46) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL25091942 0.80 BRD4 (0.58) BRD9BRD4BRD7BRD2TAF1
SCHEMBL25091955 0.79 BRD9 (0.58) BRD9BRD4BRD7BRD2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 BRD9 1/4885BRD4 17/4885BRD7 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.